Cargando…

Augmentation with antidepressants in schizophrenia treatment: benefit or risk

We focused on the application of antidepressants in schizophrenia treatment in this review. Augmentation of antidepressants with antipsychotics is a common clinical practice to treat resistant symptoms in schizophrenia, including depressive symptoms, negative symptoms, comorbid obsessive–compulsive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mao, Ye-Meng, Zhang, Ming-Dao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370910/ https://www.ncbi.nlm.nih.gov/pubmed/25834445 http://dx.doi.org/10.2147/NDT.S62266

Ejemplares similares

T232. EFFICACY AND SAFETY OF ANTIDEPRESSANT AUGMENTATION OF ANTIPSYCHOTICS IN SCHIZOPHRENIA
por: Galling, Britta, et al.
Publicado: (2018)

Randomized Controlled Trials of Add-On Antidepressants in Schizophrenia
por: Terevnikov, Viacheslav, et al.
Publicado: (2015)

Antidepressants in Spine Surgery: A Systematic Review to Determine Benefits and Risks
por: Bayoumi, Ahmed B., et al.
Publicado: (2019)

Sex Differences in Responses to Antidepressant Augmentations in Treatment-Resistant Depression
por: Moderie, Christophe, et al.
Publicado: (2022)

Accelerated antidepressant response to lithium augmentation of imipramine
por: Saini, Rajiv, et al.
Publicado: (2016)

Adjunctive antidepressive pharmacotherapy in schizophrenia patients
por: Zink, M.
Publicado: (2021)

The Gut Microbiome in Schizophrenia and the Potential Benefits of Prebiotic and Probiotic Treatment
por: Liu, Jonathan C. W., et al.
Publicado: (2021)

Blonanserin Augmentation of Atypical Antipsychotics in Patients with Schizophrenia-Who Benefits from Blonanserin Augmentation?: An Open-Label, Prospective, Multicenter Study
por: Woo, Young Sup, et al.
Publicado: (2016)

S220. BLONANSERIN AUGMENTATION IN PATIENTS WITH SCHIZOPHRENIA – WHO IS BENEFITED FROM BLONANSERIN AUGMENTATION? AN OPEN-LABEL, PROSPECTIVE, MULTI-CENTER STUDY
por: Bahk, Won-Myong, et al.
Publicado: (2018)

PM423. Blonanserin augmentation in patients with schizophrenia – who is benefited from blonanserin augmentation?: An open-label, prospective, multicenter study
por: Woo, Young Sup, et al.
Publicado: (2016)

Ghrelin Serum Concentrations Are Associated with Treatment Response During Lithium Augmentation of Antidepressants
por: Ricken, Roland, et al.
Publicado: (2017)

Antidepressants in the treatment of fibromyalgia
por: Moret, Chantal, et al.
Publicado: (2006)

Antidepressant use and psychosis hospitalization in persons with schizophrenia
por: Puranen, A., et al.
Publicado: (2023)

Augmentation Therapies as Treatments for Coexisting Somatic Problems in Schizophrenia—A Systematic Review
por: Dróżdż, Wiktor, et al.
Publicado: (2023)

Clozapine in Treatment-Resistant Schizophrenia and Its Augmentation with Electroconvulsive Therapy in Ultra-Treatment-Resistant Schizophrenia
por: Peitl, Vjekoslav, et al.
Publicado: (2023)

Potential of Heterogeneous Compounds as Antidepressants: A Narrative Review
por: Hu, Gonghui, et al.
Publicado: (2022)

Methylphenidate augmentation of escitalopram to enhance adherence to antidepressant treatment: a pilot randomized controlled trial
por: Paulus, Martin P., et al.
Publicado: (2021)

Rediscovering Psilocybin as an Antidepressive Treatment Strategy
por: Zeiss, Rene, et al.
Publicado: (2021)

Clinical Thyrotoxicosis Resulting from Liothyronine Augmentation of Antidepressant Therapy in an Adolescent
por: Pallant, Benjamin A., et al.
Publicado: (2022)

No benefit of antidepressants in inpatient treatment of depression. A longitudinal, quasi-experimental field study
por: Maß, Reinhard, et al.
Publicado: (2023)

PM358. Antidepressant Prescription pattern and Clinical Correlates for Schizophrenia
por: Kim, Jungwon, et al.
Publicado: (2016)

Antidepressants and Suicide Risk: A Comprehensive Overview
por: Pompili, Maurizio, et al.
Publicado: (2010)

A retrospective study of predictive factors for effective aripiprazole augmentation of antidepressant therapy in treatment-resistant depression
por: Sugawara, Hiroko, et al.
Publicado: (2016)

Statins and Antidepressants: A Comprehensive Review and Clinical Outlook of the Risks and Benefits of Co-prescription (2022)
por: Gutlapalli, Sai Dheeraj, et al.
Publicado: (2022)

Clinical observation on the benefits of antidepressant intervention in advanced cancer patients
por: Pu, Bing, et al.
Publicado: (2022)

Adding antidepressants to antipsychotics for treatment of subsyndromal depressive symptoms in schizophrenia: Impact on positive and negative symptoms
por: Vahia, Ipsit V., et al.
Publicado: (2013)

Antidepressive Effect of Antipsychotics in the Treatment of Schizophrenia: Meta-Regression Analysis of Randomized Placebo-Controlled Trials
por: Miura, Itaru, et al.
Publicado: (2020)

F225. LEVODOPA AUGMENTATION OF ANTIPSYCHOTICS FOR THE TREATMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
por: Foussias, George, et al.
Publicado: (2018)

Ursodeoxycholic acid augmentation in treatment-refractory schizophrenia: a case report
por: Khosravi, Mohsen
Publicado: (2020)

S194. CLOZAPINE AND ELECTROCONVULSIVE THERAPY AUGMENTATION IN ADOLESCENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA
por: Jeong Park, Kee, et al.
Publicado: (2020)

Lurasidone augmentation to clozapine in treatment resistant schizophrenia: A pilot study
por: Arienti, V., et al.
Publicado: (2023)

Quantifying the level of difficulty to treat major depressive disorder with antidepressants: Treatment Resistance to Antidepressants Evaluation Scale
por: Liu, Tzu-Yu, et al.
Publicado: (2020)

Recent advances in predicting responses to antidepressant treatment
por: Frodl, Thomas
Publicado: (2017)

Neural Plasticity Is Involved in Physiological Sleep, Depressive Sleep Disturbances, and Antidepressant Treatments
por: Zhang, Meng-Qi, et al.
Publicado: (2017)

Clinical use of antidepressant therapy and associated cardiovascular risk
por: Waring, W Stephen
Publicado: (2012)

Enhancing Neuroplasticity to Augment Cognitive Remediation in Schizophrenia
por: Jahshan, Carol, et al.
Publicado: (2017)

The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits?
por: Fornaro, Michele, et al.
Publicado: (2019)

Brassinosteroids Benefit Plants Performance by Augmenting Arbuscular Mycorrhizal Symbiosis
por: Ren, Ying, et al.
Publicado: (2021)

Long-term antidepressant use: patient perspectives of benefits and adverse effects
por: Cartwright, Claire, et al.
Publicado: (2016)

Presentation of benefits and harms of antidepressants on websites: A cross-sectional study
por: Demasi, Maryanne, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_kk7itm17ie97eem1ffagvhl3k9